
# iScience

# Article

Flu Virus Attenuates Memory Clearance of *Pneumococcus* via IFN-γ-Dependent Th17 and Independent Antibody Mechanisms



Ning Li, Xin Fan, Meiyi Xu, Ya Zhou, Beinan Wang

CellPress

wangbn@im.ac.cn

#### HIGHLIGHTS

Memory protection against bacteria was impaired in coinfection

Memory Th17 response to bacteria was reduced by IAV-induced IFN- $\gamma$ 

The Th17 reduction was caused by impeded Th17 proliferation and migration

Bacteria-specific antibody was reduced in coinfection independent of IFN- $\gamma$ 

Li et al., iScience 23, 101767 December 18, 2020 © 2020 The Author(s). https://doi.org/10.1016/ j.isci.2020.101767



# **iScience**

### Article

# Flu Virus Attenuates Memory Clearance of *Pneumococcus* via IFN-γ-Dependent Th17 and Independent Antibody Mechanisms

Ning Li,<sup>1</sup> Xin Fan,<sup>1</sup> Meiyi Xu,<sup>1,2</sup> Ya Zhou,<sup>1,2</sup> and Beinan Wang<sup>1,2,3,\*</sup>

#### SUMMARY

Bacterial coinfection is a major cause of influenza-associated mortality. Most people have experienced infections with bacterial pathogens commonly associated with influenza A virus (IAV) coinfection before IAV exposure; however, bacterial clearance through the immunological memory response (IMR) in coinfected patients is inefficient, suggesting that the IMR to bacteria is impaired during IAV infection. Adoptive transfer of CD4<sup>+</sup> T cells from mice that had experienced bacterial infection into IAV-infected mice revealed that memory protection against bacteria was weakened in the latter. Additionally, memory Th17 cell responses were impaired due to an IFN- $\gamma$ -dependent reduction in Th17 cell proliferation and delayed migration of CD4<sup>+</sup> T cells into the lungs. A bacterium-specific antibody-mediated memory response was also substantially reduced in coinfected mice, independently of IFN- $\gamma$ . These findings provide additional perspectives on the pathogenesis of coinfection and suggest additional strategies for the treatment of defective antibacterial immunity and the design of bacterial vaccines against coinfection.

#### INTRODUCTION

Influenza A virus (IAV) infection can render the host susceptible to bacterial coinfection, which is the leading cause of influenza-related death (McCullers, 2014; Morens et al., 2008). We have previously demonstrated that the IAV promotes the expression of host receptors, which facilitates bacterial adhesion to host cells and, consequently, efficient colonization (Li et al., 2015). Under normal conditions, bacterial colonization should be suppressed in immunocompetent hosts. Nevertheless, secondary bacterial infections can occur during viral clearance, suggesting that the immune response to IAV may lead to decreased immunity against bacterial infections (Brundage, 2006). Indeed, early innate responses against bacteria have been shown to be compromised as a result of a preceding viral infection (McCullers, 2014).

T-helper (Th)17 is an important T-cell subset induced by pathogenic bacteria at mucosal sites. Th17 cells are required for protective immunity against these pathogens (Rathore and Wang, 2016) and can be generated from effector memory CD4<sup>+</sup> T cells to confer rapid and efficient antibacterial immunity (van Beelen et al., 2007). Attenuation of Th17 cell responses resulting from a preceding IAV infection is an important component of the increased susceptibility to secondary bacterial pneumonia in mice (Kudva et al., 2011; Lee et al., 2017; Robinson et al., 2014, 2015). Most human populations have experienced multiple episodes of infection by the bacterial pathogens commonly associated with IAV before virus exposure. Additionally, these colonizing bacteria should have been cleared by the immunological memory response (IMR), which confers efficient immune protection. The incomplete clearance of secondary bacterial infection suggests that the bacteria-specific IMR is impaired during IAV infection. This idea is supported by a recent study showing that vaccination against pneumococcal infection was highly efficacious in the absence of IAV exposure (Metzger et al., 2015; Smith and Huber, 2018). Understanding the impact of IAV on the IMR to coinfecting bacteria could provide strategies to reduce disease severity and increase survival, as well as increase vaccine efficacy.

Interferon-gamma (IFN- $\gamma$ ) expression is induced in response to viral infection and is critical for immunity against viral and bacterial infections. Studies have indicated that IFN- $\gamma$  is responsible for the impaired

<sup>1</sup>Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China

<sup>2</sup>University of Chinese Academy of Sciences, Beijing, 100101, China

<sup>3</sup>Lead Contact

\*Correspondence: wangbn@im.ac.cn

https://doi.org/10.1016/j.isci. 2020.101767





bacterial clearance during IAV infection (Duvigneau et al., 2016; Harada et al., 2016; Sun and Metzger, 2008); however, how IFN-γ affects the IMR to bacterial infection remains unknown. We hypothesized that memory Th17 cell responses to bacteria are impaired in the presence of high levels of IFN-γ induced by IAV, leading to inefficient bacterial clearance. T-cell migration is essential for T-cell responses (Groom, 2019; Krummel et al., 2016). Unlike naive T cells that predominantly traffic to secondary lymphoid organs, memory T cells exhibit higher expression levels of chemokine receptors, which enables them to infiltrate infected nonlymphoid tissues through interactions between the chemokine receptors and their chemokine ligands (Bromley et al., 2008; Fu et al., 2013). Chemokine receptor 4 (CCR4), a major trafficking receptor expressed on memory Th17 cells, is required for their migration into the lungs through chemoattraction to its ligand, CCL17, which is highly expressed on epithelial and endothelial cells of the lungs, as well as on dendritic cells (DCs) (Mikhak et al., 2013). Maintaining sufficient numbers of memory Th17 cells in the lungs is required for efficient clearance of reinfecting bacteria (Stolberg et al., 2011).

The aim of this study was to define the mechanisms underlying the reduced immune-related clearance of bacteria after IAV infection. We showed that bacterial clearance based on immunological memory was impaired in coinfected mice. The underlying mechanism was linked to the IFN- $\gamma$ -mediated impairment of memory Th17 cell activation and migration to the lungs. In addition, the antibody-mediated memory response to *Streptococcus pneumoniae* (*Sp*) was inhibited in coinfected mice, independently of IFN- $\gamma$ . These findings reveal new perspectives on the mechanisms of coinfection, and interventions targeting these mechanisms may help to lower the risk and severity of bacterial pneumonia after IAV infection.

#### RESULTS

#### Memory-Mediated Bacterial Clearance Was Impaired in Coinfected Mice which Showed a Reduced Th17 Cell Response to Secondary *Sp* Infection

Mice were intratracheally (i.t.) inoculated with Sp or phosphate-buffered saline (PBS). After 5 weeks, the mice were reinfected with Sp, and bacterial colony-forming units (CFUs) in the lungs were determined 1, 3, and 5 days after reinfection. One day after Sp challenge, the number of CFUs was similar between PBS control and Sp-preinfected mice. However, substantially, fewer CFUs were recovered from Sp-preinfected mice compared with those treated with PBS at 3 days. Moreover, no CFUs could be recovered from Sp-preinfected mice after 5 days, whereas up to 1  $\times$  10<sup>3</sup> CFUs were detected in mice from the PBS group. This demonstrated that Sp preinfection established a memory response in the mice, which led to more efficient clearance of the infection (Figure 1A). To determine the impact of IAV infection on Sp-reactive memory T-cell responses, mice were first infected with Sp; 4 weeks later, the mice were either infected (i.t.) with a sublethal dose of the IAV PR8 strain or inoculated with PBS as a control and then challenged with the same dose of the Sp strain 7 days later (Figure 1B) (McNamee and Harmsen, 2006). Five days after Sp challenge, no CFUs were detected in the lungs of Sp-PBS-Sp-challenged mice. In contrast, ~1  $\times$  10<sup>5</sup> CFUs were detected in the PR8-preinfected mice (Sp-PR8-Sp) (Figure 1C); furthermore, mice infected with PR8 exhibited a ~20% loss of body weight 7 days after PR8 infection and another ~5% two days after the Sp challenge (Figure 1D). These results suggested that PR8 infection inhibited the IMR to Sp. To determine the mortality rate of coinfected animals, after PBS inoculation or Sp infection, the mice were challenged with a high dose of Sp following PR8 infection (PBS-PR8-Sp or Sp-PR8-Sp) or PBS inoculation (PBS-PBS-Sp or Sp-PBS-Sp). In total, 90% of the mice in the Sp-PBS-Sp group survived, whereas only 50% of the mice in the PBS-PBS-Sp group survived, demonstrating the protective effect of the IMR against Sp. Additionally, 90% of the mice in the Sp-PR8-Sp group and 80% of the mice in the PBS-PR8-Sp died (Figure 1E), suggesting that IMR to Sp was impaired following IAV infection, resulting in insufficient bacterial clearance and increased lethality.

The response of Th17 cells is critical for controlling *Sp* infection (Ramos-Sevillano et al., 2019). Flow cytometry analysis of lung cells revealed that, following *Sp* challenge, the number of CD4<sup>+</sup> IL-17<sup>+</sup> cells was substantially increased in the lungs of mice from the *Sp*-PBS-*Sp* group compared with that in mice from the *Sp*-PR8-*Sp* group; additionally, in the latter, CD4<sup>+</sup> IL-17<sup>+</sup> cell numbers were similar to those seen in nonpreinfected mice (Figures 1F, S1A, and S1B). Enzyme-linked immunosorbent assays (ELISAs) showed that the pulmonary level of IL-17 in the *Sp*-PR8-*Sp* group was substantially reduced compared with that in the *Sp*-PBS-*Sp* group (Figure 1G). Th1 cells can be activated in response to bacterial infection but are not a major Th subtype in the defense against mucosal bacterial infection (Wang et al., 2010). Compared with that observed in naive mice, Th1 cells did not respond to primary or secondary *Sp* infection, and the number of these cells was similar between the *Sp*-PR8-*Sp* and *Sp*-PBS-*Sp* groups (Figures S1C–S1E). These results suggested that the IAV reduced the response of memory Th17 cells to *Sp*.

### iScience Article






Figure 1. Memory-Mediated Bacterial Clearance Was Impaired in Coinfected Mice which Showed a Reduced Th17 Cell Response to Secondary Sp Infection

(A) Mice were intratracheally (i.t.) inoculated with Streptococcus pneumoniae (Sp) and then challenged with Sp 5 weeks later. The mice were euthanized 1, 3, or 5 days after challenge for the determination of the numbers of colony-forming units (CFUs) in the lungs.

(B) Schematic illustration of the experimental design. Mice were inoculated (i.t.) with Sp. Four weeks later, the mice were infected (i.t.) with the influenza A virus PR8 strain and challenged with Sp 7 days after infection. Five days after challenge, the mice were euthanized, and samples were taken for analyses. (C) The numbers of CFUs in the lungs were determined 5 days after challenge (n = 4-9).

(D) Body weight was measured once daily (n = 4).

(E) Mice were infected as in (B) but were challenged with a high dose of Sp following PR8 infection. The mortality rate was recorded daily (n = 10). Mice were infected, challenged, and euthanized as described in (B).

(F) The proportion of IL-17<sup>+</sup> cells among pulmonary CD4<sup>+</sup> T cell population was determined by flow cytometry (n = 6-8).

(G) IL-17 concentration in lung homogenates was determined by ELISA (n = 6-8).

Data are represented as mean  $\pm$  SEM of 2–3 independent experiments. \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001, \*\*\*p < 0.0001. (A and C) Two-tailed unpaired Mann-Whitney U nonparametric t test; (E) log rank test; (F and G) one-way ANOVA, followed by Tukey's multiple comparisons test.

# The Severity of Coinfection Was Associated with an Increased IFN- $\gamma$ Response to IAV Infection

Mortality among coinfected mice has been reported to peak 6–7 days after IAV infection (McCullers and Rehg, 2002; McNamee and Harmsen, 2006). Here, we found that the pulmonary level of IFN- $\gamma$  peaked 7 days after PR8 inoculation (Figure 2A) and that NK cells (37%) and CD4<sup>+</sup> T cells (33%) were the main IFN- $\gamma$ -secreting cells (Figure 2B), suggestive of a link between IFN- $\gamma$  and disease severity. To verify this possibility, *Sp*-preinfected *Ifng*<sup>-/-</sup> mice were inoculated with PR8 and challenged with *Sp* as described above. The number of CFUs recovered from the lungs 5 days after *Sp* challenge was ~100-fold lower in *Ifng*<sup>-/-</sup> mice than in wild-type (WT) mice (Figure 2C), and *Ifng*<sup>-/-</sup> mice displayed a faster recovery of body weight (Figure 2D). A lethality assay showed that >70% of the *Ifng*<sup>-/-</sup> mice survived, compared with only 38% for the WT mice (Figure 2E). These results suggested that the increased IFN- $\gamma$  level in response to IAV was linked to impaired memory-induced bacterial clearance.

# $\mbox{IFN-}\gamma$ Deficiency Rescued the Response of Memory Th17 Cells to the Bacteria in Coinfected Mice

Based on the correlation between IFN- $\gamma$  induction and the low efficiency of bacterial clearance, we speculated that IFN- $\gamma$  inhibits the response of memory Th17 cells to *Sp*. To test this, *Ifng*<sup>-/-</sup> mice were preinfected with *Sp*, and the levels of IL-17 produced by the splenocytes were measured as an indicator of Th17






Figure 2. The Severity of Coinfection Was Associated with an Increased IFN- $\gamma$  Response to IAV Infection (A) IFN- $\gamma$  concentration in lung homogenates after infection with the influenza A virus PR8 strain was determined by ELISA (n = 4).

(B) The proportion of CD4<sup>-</sup> NK1.1<sup>+</sup> cells, CD3<sup>+</sup> CD4<sup>+</sup> cells, or CD3<sup>+</sup> CD8<sup>+</sup> cells among IFN- $\gamma^+$  cell population in the lungs was determined by flow cytometry 7 days after PR8 infection (*n* = 3). Mice were infected, challenged, and euthanized as described in Figure 1B.

(C) The numbers of colony-forming units (CFUs) in the lungs were counted (n = 9-11).

(D) Body weight was measured as described in Figure 1D (n = 6).

(E) Mice were infected and challenged as described in Figure 1E. The mortality rate was recorded daily (n = 20).

Data are represented as mean  $\pm$  SEM of 2–3 independent experiments. \*p < 0.05, \*\*p < 0.01, \*\*\*\*p < 0.001. (A) One-way ANOVA, followed by Tukey's multiple comparisons test; (C) 2-tailed unpaired Mann-Whitney U nonparametric t test; (E) log rank test.

cell activation. ELISAs revealed that both WT and  $Ifng^{-/-}$  mice produced IL-17 in response to heat-killed Sp (HK-Sp) treatment; however, the levels of IL-17 were ~50-fold higher in  $Ifng^{-/-}$  mice than in WT mice (Figure 3A). To further determine the role of IFN- $\gamma$  in the response of memory Th17 cells, splenocytes were isolated from Sp-preinfected WT mice and coincubated with IFN-Y in the presence of HK-Sp. ELISAs performed on the culture supernatant showed that the IL-17 recall response to HK-Sp was reduced in an IFN- $\gamma$  dose-dependent manner (Figure 3B). Compared with WT mice, IL-17 production was much higher in splenocytes derived from Sp-preinfected  $Ifng^{-/-}$  mice and was inhibited more markedly by exogenous IFN-γ (Figure S2A). To confirm this observation, in vivo experiments were carried out. Sp-preinfected  $Ifng^{-/-}$  mice and WT mice were coinfected as described in Figure 1B, and the response of pulmonary Th17 cells was analyzed by flow cytometry. Higher numbers of  $CD4^+$  IL-17<sup>+</sup> cells were detected in *Ifng*<sup>-/</sup> mice than in WT mice (Figures 3C, 3D, and S2B), and a similar propensity was observed for IL-17 production in lung homogenates obtained from Ifng<sup>-/-</sup> mice (Figure 3E). To confirm these in vivo findings, Sp-preinfected  $Ifng^{-\prime-}$  mice were administered IFN- $\gamma$  i.t. and intravenously to simulate IFN- $\gamma$  induction by PR8 (Figure 3F). As expected, IFN-γ-treated mice displayed fewer pulmonary CD4<sup>+</sup> IL-17<sup>+</sup> cells and lower expression of IL-17 in response to Sp challenge (Figures 3G-3I and S2C). These data suggested that IFN- $\gamma$ restricted the activation of memory Th17 cell responses. We noticed that the response of memory Th17 cells/IL-17 in Ifng<sup>-/-</sup> mice of the Sp-PR8-Sp group was not completely reversed to the levels observed in WT mice of the Sp-PBS-Sp group, indicating that other mechanisms may be involved in the impaired memory Th17 cell response. To verify that the rescued memory Th17 cell response was responsible for the



Article






Figure 3. IFN- $\gamma$  Deficiency Rescued the Response of Memory Th17 Cells to the Bacteria in Coinfected Mice

(A and B) (A) Splenocytes from different groups of mice were cultured with or without heat-killed *Streptococcus pneumoniae* (HK-*Sp*) or (B) costimulated with the indicated concentration of recombinant mouse IFN- $\gamma$  for 7 days (n = 6). IL-17 concentration in the culture supernatants was measured by ELISA. Mice were infected, challenged, and euthanized as shown in Figure 1B.

(C and D) (C) The number of pulmonary IL-17<sup>+</sup> CD4<sup>+</sup> T cells and (D) the proportion of IL-17<sup>+</sup> cells among CD4<sup>+</sup> T cell population in the lungs were determined by flow cytometry (*n* = 3–8).

(E) IL-17 concentration in lung homogenates was measured by ELISA (n = 6-8).

(F) Schematic illustration of the experimental design for recombinant mouse IFN- $\gamma$  treatment and infection in the mice.

(G and H) (G) The number of pulmonary IL-17<sup>+</sup> CD4<sup>+</sup> T cells and (H) the proportion of IL-17<sup>+</sup> cells among CD4<sup>+</sup> T cell population in the lungs were detected by flow cytometry.


(I) IL-17 concentration in lung homogenates was measured by ELISA.

(J)  $Ifng^{-/-}$  mice were infected and challenged as described in Figure 1B and were intraperitoneally injected with neutralizing antibody directed against IL-17 (isotype antibody was used as a control) every other day after infection with the influenza A virus PR8 strain. The numbers of colony-forming units (CFUs) in the lungs were determined 5 days after challenge (n = 3-4).

Data are represented as mean  $\pm$  SEM of 2–3 independent experiments. \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001, \*\*\*\*p < 0.001. (A-E and G-I) One-way analysis of variance (ANOVA) A, followed by Tukey's multiple comparisons test; (J) 2-tailed unpaired Mann-Whitney U nonparametric t test.







### Figure 4. The Activation of DCs and IL-23 Produced by DCs Were Both Inhibited in IAV-Infected Mice Independently of IFN- $\!\gamma$

Mice were infected and challenged as described in Figure 1B. Two days after Streptococcus pneumoniae (Sp) challenge, the mice were euthanized, and lung samples were taken for dendritic cell (DC) analyses (n = 4).

(A–C) (A) The number of CD11c<sup>+</sup> cells in the lungs and the mean fluorescence intensity (MFI) for (B) MHC class II and (C) CD86 on the surface of DCs were determined by flow cytometry.

(D and E) (D) IL-23 and (E) IL-12p70 concentration in lung homogenates was determined by ELISA.

(F) Mice were infected, challenged, and euthanized as described in Figure 1B. IL-23 concentration in lung homogenates was determined by ELISA (n = 9-11).

Data are represented as mean  $\pm$  SEM of 2–3 independent experiments. ns, not significant, \*p < 0.05, \*\*p < 0.01,

\*\*\* p < 0.001 , \*\*\*\* p < 0.0001 . (A-F) One-way ANOVA, followed by Tukey's multiple comparisons test.

improved bacterial clearance under conditions of IFN- $\gamma$  deficiency,  $Ifng^{-/-}$  mice were infected as described in Figure 1B and intraperitoneally injected with IL-17 neutralizing antibody following PR8 infection, following which the numbers of CFUs in the lungs of the mice were determined. The results revealed that, although statistical significance was not reached, mice that received IL-17 neutralizing antibody exhibited a greater bacterial load relative to those receiving the isotype control antibody (Figure 3J). These data demonstrated that PR8-induced IFN- $\gamma$  inhibits the protection against *Sp* by suppressing memory Th17 cell responses.

# The Activation of DCs and IL-23 Produced by DCs Were Both Inhibited in IAV-Infected Mice Independently of IFN- $\gamma$

DCs play a critical role in T-cell activation. To determine the mechanisms underlying the reduction in Th17 cell responses, we examined the effect of PR8 infection on DCs. Mice were infected as described in Figure 1B and euthanized 2 days after *Sp* challenge, the time when the activation of DCs reached the peak point (data not shown). We found that the levels of pulmonary DCs were substantially higher in PBS-PR8-*Sp*- and *Sp*-PR8-*Sp*-treated mice than in matching, PR8-uninfected controls (Figure 4A). Flow cytometry analysis revealed that the expression of MHC class II and CD86 was lower in PR8-infected mice (Figures 4B, 4C and, S3A). DCs are a primary source of IL-23 secretion, and IL-23 is important for memory T-cell proliferation and IL-17 secretion (Li et al., 2019). ELISAs conducted on lung tissue supernatants showed that the levels of IL-23 were substantially reduced in PR8-infected mice irrespective of whether the mice had been preinfected or not (Figure 4D). The level of IL-12, a cytokine predominantly produced by activated DCs (Kaka et al., 2008), was also lower in the *Sp*-PR8-*Sp* treatment group than in the other groups (Figure 4E).





Similar DC-related changes were also observed in the hilar lymph nodes (HLNs) (Figures S3B–S3F). These results suggested that DC activation was inhibited following PR8 infection. To determine the effects of IFN- $\gamma$  on the DC-related changes, IL-23 production was examined 5 days after challenge. As shown in Figure 4F, much higher levels of IL-23 were found at this time (400 pg/mL) than those detected at 2 days (40 pg/mL) in *Sp*-PBS-*Sp* groups. However, the levels were equal between WT- and *Ifng*<sup>-/-</sup>-coinfected mice and much lower than those in *Sp*-PBS-*Sp* mice. These results indicated that the reduction in IL-23 levels observed in WT mice was not rescued in *Ifng*<sup>-/-</sup> mice and supported that DC inactivation was IFN- $\gamma$  independent.

It has been reported that IFN- $\gamma$  inhibits memory Th17 cells through indoleamine 2,3-dioxygenase (IDO) produced by antigen presenting cells (APCs) in a mouse model of collagen-induced arthritis (Lee et al., 2013). To test whether the same mechanism was involved in Th17 cell inhibition, coinfected mice were administered the IDO inhibitor 1-methyl-D-tryptophan in drinking water before, during, and after PR8 infection (Figure S4A). We found that the percentages and numbers of pulmonary Th17 cells were similar between IDO inhibitor- and vehicle control-treated mice (Figures S4B and S4C). Moreover, no differences in the numbers of lung-derived CFUs or body weight loss were found between the two groups of mice (Figures S4D and S4E). These data indicated that the IFN- $\gamma$ -dependent IDO pathway found in the non-infection model was not involved in the impairment of Th17 cell responses observed during coinfection.


#### The Proliferation of Th17 Cells in Response to Secondary *Sp* Infection Was Suppressed in IAV-Infected Mice

To analyze the mechanisms underlying the reduction in the number of Th17 cells, OT-Iltransgenic mice (CD45.2) were preinfected with a previously generated Streptococcus pyogenes strain that expresses the ovalbumin 323-339 peptide (GAS<sup>OVA</sup>) (Park et al., 2004). Streptococcus pyogenes is a bacterium that is also frequently associated with coinfection. Four weeks after infection, CD4<sup>+</sup> T cells were isolated from infected mice or naive OT-Iltransgenic mice, stained with carboxyfluorescein succinimidyl ester, and transferred to recipient mice (CD45.1) that had been infected with PR8 6 days previously. Twentyfour hours after transfer, the recipient mice were infected (i.t.) with GAS<sup>OVA</sup> (Caucheteux et al., 2017) (Figure 5A). Cells in the HLNs of the recipient mice were analyzed 3 days after GAS<sup>OVA</sup> infection. Flow cytometry analysis revealed that the number of CD4<sup>+</sup> CD45.2<sup>+</sup> donor cells derived from GAS<sup>OVA</sup>-preinfected mice was lower in PR8-infected recipients than in those treated with PBS (Figures 5B, 5C, and S5A). A similar reduction in the number of donor cells was observed in PR8-infected recipients when naive donor cells were used, suggesting that PR8 infection inhibited the proliferation of both primary and memory T cells. Flow cytometry analysis of HLN cells revealed that the numbers of fast-dividing (>4 times) donor cells (Figures 5D and 5E) and CD4<sup>+</sup> CD45.2<sup>+</sup> T cells expressing ROR<sub>Y</sub>t<sup>+</sup> (a lineage-defining transcription factor) in PR8-infected recipients were also substantially lower than those in PBS-treated recipients (Figures 5F, 5G, and S5B). These data suggested that PR8 infection inhibited the proliferation of CD4<sup>+</sup> T cells, especially Th17 cells, in response to secondary bacterial infection.

# The Trafficking of Th17 Cells to the Lungs Was Delayed in Coinfected Mice in Response to Secondary Sp Infection

The homing of T cells to specific tissues is crucial for evoking a robust immune response in infected sites (Tufail et al., 2013). CCR4 is a major trafficking molecule expressed on Th17 cells that is required to guide their recruitment to the lungs via CCL17 (Matsuo et al., 2016; Mikhak et al., 2013). To ascertain whether the reduction in the number of Th17 cells in the lungs was due to reduced T-cell migration, quantitative realtime PCR (gPCR) was carried out. The pulmonary expression of CCL17 was similar between Sp-preinfected mice and naive mice (Figure 6A, columns 1 and 3) and was substantially increased in mice from the Sp-PBS-Sp group (Figure 6A, column 5). In contrast, CCL17 expression remained at a basal level in Sp-PR8-Sp-coinfected mice (Figure 6A, column 7). Meanwhile, the CCL17 expression pattern was similar in  $Ifng^{-/-}$  mice but was much higher in response to Sp challenge (Figure 6A, gray columns). Further analyses of CCL17 expression in lung tissue by immunohistochemistry (Figure 6B, left) and the subsequent quantification of staining intensity (Figure 6B, right) revealed that the lower CCL17-positive rate in the Sp-PR8-Sp group was relative to that in the Sp-PBS-Sp group. The positive rate was markedly higher in  $Ifng^{-/-}$  mice than in WT mice following Sp-PR8-Sp treatment. These results suggested that IFN- $\gamma$  contributed to the reduction in CCL17 expression in the lungs of coinfected mice. We also examined the levels of CCR4 on CD4<sup>+</sup> T cells. Flow cytometric analysis revealed that the percentile of pulmonary CD4<sup>+</sup> CCR4<sup>+</sup> cells in Sp-PR8-Sp-treated  $Ifng^{-/-}$  mice was as high as that in Sp-PBS-Sp-treated WT mice (Figure S6A, columns 5 and





**iScience** 

Article

Figure 5. The Proliferation of Th17 Cells in Response to Secondary Sp Infection Was Suppressed in IAV-Infected Mice

(A) Schematic illustration of adoptive transfer and mouse infection. The hilar lymph nodes (HLNs) of the recipients were removed for flow cytometric analyses. (B–G) (B) The number of donor CD4<sup>+</sup> T cells and (C) the proportion of donor CD4<sup>+</sup> T cells among the total CD4<sup>+</sup> T cell population; (D) the proportion of fast-proliferating cells among the donor CD4<sup>+</sup> T cell population and (E) the number of fast-proliferating cells; and (F) the proportion of ROR $\gamma$ t<sup>+</sup> cells among the donor CD4<sup>+</sup> T cell population and (G) the number of ROR $\gamma$ t<sup>+</sup> CD4<sup>+</sup> donor T cells were determined by flow cytometry. Data are represented as mean ± SEM of 2–3 independent experiments. \*p < 0.05, \*\*\*\*p < 0.0001. (B–G) One-way ANOVA, followed by Tukey's multiple

8) and that in *Sp*-PR8-*Sp*-coinfected WT mice was lower (Figure S6A, column 7). However, the numbers of CD4<sup>+</sup> CCR4<sup>+</sup> cells were similar between WT and  $lfng^{-/-}$  mice (Figure S6B). These data suggested that IFN- $\gamma$  restricts the migration of Th17 cells to the lungs mainly through the downregulation of CCL17 expression in coinfected lung tissue. To further verify this, CD4<sup>+</sup> T cells from GAS<sup>OVA</sup>-infected OT-IItransgenic mice were transferred to PR8-infected recipient mice. Flow cytometry revealed that, after challenge with GAS<sup>OVA</sup>, the number and percentile of CD4<sup>+</sup> CD45.2<sup>+</sup> donor cells in the lungs of PR8-infected GAS<sup>OVA</sup> recipients were significantly lower than those in the lungs of PBS-treated GAS<sup>OVA</sup> recipients (Figures 6C, 6D, and S6C). Similar results were found when ROR $\gamma$ t<sup>+</sup> donor cells in the lungs were examined (Figures 6E, 6F, and S6D). These results suggested that IAV infection impeded the trafficking of Th17 cells to the lungs in response to secondary bacterial infection.

# Memory Antibody Responses to Sp Were Reduced in Coinfected Mice Independently of IFN- $\gamma$

The Sp recall clearance was partially rescued in coinfected  $Ifng^{-/-}$  mice, suggesting that other, IFN- $\gamma$ -independent mechanisms were involved. The antibody-mediated memory response is important for the elimination of re-entry pathogens through opsonophagocytosis and neutralization. Therefore, we measured the serum levels of Sp-specific IgG using ELISAs. IgG production was strongly induced in response to Sp challenge in the Sp-PBS-Sp group but markedly inhibited in the Sp-PR8-Sp group (Figure 7). However, different from the response of Th17 cells, IgG production was not rescued in coinfected  $Ifng^{-/-}$ mice (Figure 7), suggesting that IAV infection inhibited the memory antibody response to Sp through IFN- $\gamma$ -independent mechanisms.

#### DISCUSSION

comparisons test.

Immunological memory is long lived and responds rapidly and effectively to previously encountered pathogens (Janeway, 2001). Given that most human populations have experienced respiratory infections with the bacterial pathogens commonly found in IAV coinfection, the inefficient bacterial clearance during coinfection is likely attributable to an impaired IMR to the invading bacteria.








Figure 6. The Trafficking of Th17 Cells to the Lungs Was Delayed in Coinfected Mice in Response to Secondary Sp Infection Mice were infected, challenged, and euthanized as described in Figure 1B.

(A) The relative expression of CCL17 in lung cells was determined by qPCR (n = 6-8).

(B) Immunohistochemical staining of lung sections using an anti-CCL17 antibody. Scale bar represents 200  $\mu$ m (left). The positive rate of CCL17 expression cells was assessed (right). The adoptive transfer was performed as described in Figure 5A. The lungs of recipients were removed for flow cytometric analyses (n = 3-4).


(C–F) (C) The number of donor CD4<sup>+</sup> T cells and (D) the proportion of donor CD4<sup>+</sup> T cells among the total CD4<sup>+</sup> T cell population and (E) the number of ROR $\gamma$ t<sup>+</sup> CD4<sup>+</sup> donor T cells and (F) the proportion of ROR $\gamma$ t<sup>+</sup> cells among the donor CD4<sup>+</sup> T cell population were determined by flow cytometry. Data are represented as mean  $\pm$  SEM of 2–3 independent experiments. \*p < 0.05, \*\*p < 0.01, \*\*\*\*p < 0.001, \*\*\*\*p < 0.0001. (A–F) One-way ANOVA, followed by Tukey's multiple comparisons test.

In the present study, we found that the responses by memory Th17 cells and antibodies to pneumococcal infection were attenuated during IAV infection, leading to impaired bacterial clearance and increased lethality. We demonstrated that the impaired memory Th17 response resulted from an IFN- $\gamma$ -dependent reduction of Th17 proliferation and lung trafficking of Th17 cells and that the attenuated antibody recall response to bacterial infection was IFN- $\gamma$  independent.

IFN- $\gamma$  is a multipotent cytokine responsible for the modulation of many facets of the immune response (Zha et al., 2017). Although we demonstrated that the restriction of memory Th17 cells played an important part in bacterial clearance, other IFN- $\gamma$ -dependent mechanisms may also have contributed, such as the inhibition of alveolar macrophages during bacterial clearance (Sun and Metzger, 2008). In addition, the partially reversed memory-mediated bacterial clearance and CCL17 expression in the lungs of *Ifng*<sup>-/-</sup> mice also suggest that other IFN- $\gamma$ -independent mechanisms are involved. Studies have shown that IAV infection can induce IFN- $\gamma$ -independent DC differentiation defects in the bone marrow (Beshara et al., 2018), while type I IFNs can attenuate Th17 response *via* the suppression of IL-23 production by DCs (Kudva et al., 2011). Similarly, we found that IAV infection inhibits the activation of lung DCs and decreases IL-23 production by DCs independently of IFN- $\gamma$ . Given the critical role of IL-23 in the regulation of memory Th17 cell function, the impaired activation of DCs during IAV infection might be responsible for the residual IFN- $\gamma$ -independent impairment of *Sp* clearance, along with other mechanisms such as the type I IFN-mediated inhibition of neutrophil and macrophage chemotaxis (Nakamura et al., 2011; Shahangian et al., 2009) and restriction of IL-17-producing  $\gamma\delta$  T cells (Li et al., 2012).









Although IFN- $\gamma$  has been shown to downregulate Th17 cell differentiation *in vitro* (Harrington et al., 2005; Nakae et al., 2007), similar results have not been evidenced *in vivo*. Mouse experiments have shown that a reduced Th17 response to bacterial infection in IAV-preinfected mice requires the production of type I IFNs but is independent of IFN- $\gamma$  (Kudva et al., 2011; Lee et al., 2015). IFN- $\gamma$  is primarily produced during the adaptive immune response by NK cells, activated CD8 cells, and Th1 cells, whereas type I IFNs are normally produced by innate immune cells at the early stage of infection. Type I IFNs may mediate Th17 cell differentiation during the primary T-cell response to bacteria as naive specific pathogen-free mice have not established memory response to primary bacterial infection.

The mechanisms underlying the IFN- $\gamma$ -mediated attenuation of memory Th17 responses are mostly unknown. The IFN- $\gamma$ -mediated downregulation of the expression of the chemokine responsible for Th17 cell trafficking to infected lungs (CCL17) may reflect an IFN- $\gamma$  regulation of T cells in the context of the more complex environment of inflammation. The underlying mechanisms will be further identified in our future studies.

Secondary bacterial infection in the lungs is also associated with viruses other than IAV (Li et al., 2015; McCullers, 2014) and occurs in different mucosal sites, such as the middle ear and genitourinary tract (Brockson et al., 2012; Marom et al., 2012; Smith and McCullers, 2014; Torcia, 2019). IFN- $\gamma$  expression is commonly induced during viral infections (Le Nouen et al., 2010), and Th17 is the primary T-cell subtype activated for bacterial clearance at mucosal sites. Hence, a defect in the IMR might be a common mechanism that contributes markedly to impaired bacterial clearance in the pathogenesis of viral-bacterial coinfection. Targeting this mechanism may be a valuable addition to the treatment options for refractory bacterial infections at mucosal sites.

### iScience Article



The IFN- $\gamma$ -mediated regulation of memory Th17 cells may not be involved in the reduced efficacy of pneumococcal vaccines because Th17 cells are not primarily induced through the intramuscular route used for the administration of such vaccines. However, our results revealed that the memory antibody response to coinfected *Sp* is impaired, which is consistent with the partially reduced humoral immunity against the bacteria following *Sp* vaccination in coinfected mice. Future studies are needed to clarify the underlying mechanisms so as to overcome the IAV-induced defects in the efficacy of the bacterial vaccine.

#### **Limitations of the Study**

Although we demonstrated that IFN- $\gamma$  impaired memory Th17 response to bacterial infection through inhibition of Th17 proliferation and migration and ruled out the role of IDO in suppressing Th17 responses in a model of an autoimmune disease, how IFN- $\gamma$  causes the inhibition was not studied.

#### **Resource Availability**

#### Lead Contact

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Beinan Wang (wangbn@im.ac.cn).

#### Materials Availability

This study did not generate new unique reagents.

#### Data and Code Availability

No data sets or code were generated or analyzed in this study. The raw data supporting the current study are available from the Lead Contact upon request. All software is commercially available.

#### **METHODS**

All methods can be found in the accompanying Transparent Methods supplemental file. The antibodies, organisms/strains, viral and bacterial strains, recombinant proteins, chemicals, critical commercial assays, oligonucleotides, and main software used in this study are listed in Table S1.

#### SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at https://doi.org/10.1016/j.isci.2020.101767.

#### ACKNOWLEDGMENTS

We thank Dr. B. Hou and J. Hao (Institute of Biophysics, Chinese Academy of Sciences, Beijing, China) for providing OT-Iltransgenic mice and immunohistochemistry experiments. This work was supported by the National Natural Science Foundation of China, China (NSFC) (31670931) to B.W. and (31600737) to N.L. for Young Scholars.

#### **AUTHOR CONTRIBUTIONS**

Conceptualization, B.W. and N.L.; Methodology, B.W., N.L., and X.F.; Investigation, N.L., X.F., M.X., and Y.Z.; Writing –Original Draft, N.L.; Writing –Review & Editing, B.W.; Supervision, B.W.; Funding Acquisition, B.W. and N.L.

#### **DECLARATION OF INTERESTS**

The authors declare no competing interests.

Received: November 22, 2019 Revised: June 16, 2020 Accepted: October 30, 2020 Published: December 18, 2020



#### REFERENCES

Beshara, R., Sencio, V., Soulard, D., Barthelemy, A., Fontaine, J., Pinteau, T., Deruyter, L., Ismail, M.B., Paget, C., Sirard, J.C., et al. (2018). Alteration of Flt3-Ligand-dependent de novo generation of conventional dendritic cells during influenza infection contributes to respiratory bacterial superinfection. PLoS Pathog. 14, e1007360.

Brockson, M.E., Novotny, L.A., Jurcisek, J.A., McGillivary, G., Bowers, M.R., and Bakaletz, L.O. (2012). Respiratory syncytial virus promotes Moraxella catarrhalis-induced ascending experimental otitis media. PLoS One 7, e40088.

Bromley, S.K., Mempel, T.R., and Luster, A.D. (2008). Orchestrating the orchestrators: chemokines in control of T cell traffic. Nat. Immunol. *9*, 970–980.

Brundage, J.F. (2006). Interactions between influenza and bacterial respiratory pathogens: implications for pandemic preparedness. Lancet Infect. Dis. *6*, 303–312.

Caucheteux, S.M., Hu-Li, J., Mohammed, R.N., Ager, A., and Paul, W.E. (2017). Cytokine regulation of lung Th17 response to airway immunization using LPS adjuvant. Mucosal Immunol. 10, 361–372.

Duvigneau, S., Sharma-Chawla, N., Boianelli, A., Stegemann-Koniszewski, S., Nguyen, V.K., Bruder, D., and Hernandez-Vargas, E.A. (2016). Hierarchical effects of pro-inflammatory cytokines on the post-influenza susceptibility to pneumococcal coinfection. Sci. Rep. *6*, 37045.

Fu, H., Wang, A., Mauro, C., and Marelli-Berg, F. (2013). T lymphocyte trafficking: molecules and mechanisms. Front. Biosci. (Landmark Ed.) *18*, 422–440.

Groom, J.R. (2019). Regulators of T-cell fate: integration of cell migration, differentiation and function. Immunol. Rev. 289, 101–114.

Harada, T., Ishimatsu, Y., Hara, A., Morita, T., Nakashima, S., Kakugawa, T., Sakamoto, N., Kosai, K., Izumikawa, K., Yanagihara, K., et al. (2016). Premedication with clarithromycin is effective against secondary bacterial pneumonia during influenza virus infection in a pulmonary emphysema mouse model. J. Pharmacol. Exp. Ther. *358*, 457–463.

Harrington, L.E., Hatton, R.D., Mangan, P.R., Turner, H., Murphy, T.L., Murphy, K.M., and Weaver, C.T. (2005). Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. *6*, 1123–1132.

Janeway, C.A., Jr. (2001). How the immune system works to protect the host from infection: a personal view. Proc. Natl. Acad. Sci. U S A *98*, 7461–7468.

Kaka, A.S., Foster, A.E., Weiss, H.L., Rooney, C.M., and Leen, A.M. (2008). Using dendritic cell maturation and IL-12 producing capacity as markers of function: a cautionary tale. J. Immunother. *31*, 359–369.

Krummel, M.F., Bartumeus, F., and Gerard, A. (2016). T cell migration, search strategies and mechanisms. Nat. Rev. Immunol. 16, 193–201. Kudva, A., Scheller, E.V., Robinson, K.M., Crowe, C.R., Choi, S.M., Slight, S.R., Khader, S.A., Dubin, P.J., Enelow, R.I., Kolls, J.K., et al. (2011). Influenza A inhibits Th17-mediated host defense against bacterial pneumonia in mice. J. Immunol. *186*, 1666–1674.

Le Nouen, C., Hillyer, P., Munir, S., Winter, C.C., McCarty, T., Bukreyev, A., Collins, P.L., Rabin, R.L., and Buchholz, U.J. (2010). Effects of human respiratory syncytial virus, metapneumovirus, parainfluenza virus 3 and influenza virus on CD4+ T cell activation by dendritic cells. PLoS One 5, e15017.

Lee, B., Gopal, R., Manni, M.L., McHugh, K.J., Mandalapu, S., Robinson, K.M., and Alcorn, J.F. (2017). STAT1 is required for suppression of type 17 immunity during influenza and bacterial superinfection. Immunohorizons 1, 81–91.

Lee, B., Robinson, K.M., McHugh, K.J., Scheller, E.V., Mandalapu, S., Chen, C., Di, Y.P., Clay, M.E., Enelow, R.I., Dubin, P.J., et al. (2015). Influenzainduced type I interferon enhances susceptibility to gram-negative and gram-positive bacterial pneumonia in mice. Am. J. Physiol. Lung Cell Mol. Physiol. 309, L158–L167.

Lee, J., Lee, J., Park, M.K., Lim, M.A., Park, E.M., Kim, E.K., Yang, E.J., Lee, S.Y., Jhun, J.Y., Park, S.H., et al. (2013). Interferon gamma suppresses collagen-induced arthritis by regulation of Th17 through the induction of indoleamine-2,3deoxygenase. PLoS One 8, e60900.

Li, N., Ren, A., Wang, X., Fan, X., Zhao, Y., Gao, G.F., Cleary, P., and Wang, B. (2015). Influenza viral neuraminidase primes bacterial coinfection through TGF-beta-mediated expression of host cell receptors. Proc. Natl. Acad. Sci. U S A *112*, 238–243.

Li, W., Moltedo, B., and Moran, T.M. (2012). Type I interferon induction during influenza virus infection increases susceptibility to secondary Streptococcus pneumoniae infection by negative regulation of gammadelta T cells. J. Virol. *86*, 12304–12312.

Li, Y., Yu, X., Ma, Y., and Hua, S. (2019). IL-23 and dendritic cells: what are the roles of their mutual attachment in immune response and immunotherapy? Cytokine 120, 78–84.

Marom, T., Nokso-Koivisto, J., and Chonmaitree, T. (2012). Viral-bacterial interactions in acute otitis media. Curr. Allergy Asthma Rep. 12, 551–558.

Matsuo, K., Itoh, T., Koyama, A., Imamura, R., Kawai, S., Nishiwaki, K., Oiso, N., Kawada, A., Yoshie, O., and Nakayama, T. (2016). CCR4 is critically involved in effective antitumor immunity in mice bearing intradermal B16 melanoma. Cancer Lett. *378*, 16–22.

McCullers, J.A. (2014). The co-pathogenesis of influenza viruses with bacteria in the lung. Nat. Rev. Microbiol. *12*, 252–262.

McCullers, J.A., and Rehg, J.E. (2002). Lethal synergism between influenza virus and Streptococcus pneumoniae: characterization of a mouse model and the role of platelet-activating factor receptor. J. Infect. Dis. *186*, 341–350. McNamee, L.A., and Harmsen, A.G. (2006). Both influenza-induced neutrophil dysfunction and neutrophil-independent mechanisms contribute to increased susceptibility to a secondary Streptococcus pneumoniae infection. Infect. Immun. 74, 6707–6721.

**iScience** 

Article

Metzger, D.W., Furuya, Y., Salmon, S.L., Roberts, S., and Sun, K. (2015). Limited efficacy of antibacterial vaccination against secondary serotype 3 pneumococcal pneumonia following influenza infection. J. Infect. Dis. *212*, 445–452.

Mikhak, Z., Strassner, J.P., and Luster, A.D. (2013). Lung dendritic cells imprint T cell lung homing and promote lung immunity through the chemokine receptor CCR4. J. Exp. Med. 210, 1855–1869.

Morens, D.M., Taubenberger, J.K., and Fauci, A.S. (2008). Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J. Infect. Dis. 198, 962–970.

Nakae, S., Iwakura, Y., Suto, H., and Galli, S.J. (2007). Phenotypic differences between Th1 and Th17 cells and negative regulation of Th1 cell differentiation by IL-17. J. Leukoc. Biol. *81*, 1258– 1268.

Nakamura, S., Davis, K.M., and Weiser, J.N. (2011). Synergistic stimulation of type I interferons during influenza virus coinfection promotes Streptococcus pneumoniae colonization in mice. J. Clin. Invest. 121, 3657–3665.

Park, H.S., Costalonga, M., Reinhardt, R.L., Dombek, P.E., Jenkins, M.K., and Cleary, P.P. (2004). Primary induction of CD4 T cell responses in nasal associated lymphoid tissue during group A streptococcal infection. Eur. J. Immunol. 34, 2843–2853.

Ramos-Sevillano, E., Ercoli, G., and Brown, J.S. (2019). Mechanisms of naturally acquired immunity to Streptococcus pneumoniae. Front. Immunol. *10*, 358.

Rathore, J.S., and Wang, Y. (2016). Protective role of Th17 cells in pulmonary infection. Vaccine *34*, 1504–1514.

Robinson, K.M., Kolls, J.K., and Alcorn, J.F. (2015). The immunology of influenza virus-associated bacterial pneumonia. Curr. Opin. Immunol. *34*, 59–67.

Robinson, K.M., McHugh, K.J., Mandalapu, S., Clay, M.E., Lee, B., Scheller, E.V., Enelow, R.I., Chan, Y.R., Kolls, J.K., and Alcorn, J.F. (2014). Influenza A virus exacerbates Staphylococcus aureus pneumonia in mice by attenuating antimicrobial peptide production. J. Infect. Dis. 209, 865–875.

Shahangian, A., Chow, E.K., Tian, X., Kang, J.R., Ghaffari, A., Liu, S.Y., Belperio, J.A., Cheng, G., and Deng, J.C. (2009). Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice. J. Clin. Invest. *119*, 1910– 1920.

Smith, A.M., and Huber, V.C. (2018). The unexpected impact of vaccines on secondary bacterial infections following influenza. Viral Immunol. *31*, 159–173.

### iScience Article



Smith, A.M., and McCullers, J.A. (2014). Secondary bacterial infections in influenza virus infection pathogenesis. Curr. Top. Microbiol. Immunol. 385, 327–356.

Stolberg, V.R., Chiu, B.C., Schmidt, B.M., Kunkel, S.L., Sandor, M., and Chensue, S.W. (2011). CC chemokine receptor 4 contributes to innate NK and chronic stage T helper cell recall responses during Mycobacterium bovis infection. Am. J. Pathol. *178*, 233–244.

Sun, K., and Metzger, D.W. (2008). Inhibition of pulmonary antibacterial defense by interferongamma during recovery from influenza infection. Nat. Med. 14, 558–564. Torcia, M.G. (2019). Interplay among vaginal microbiome, immune response and sexually transmitted viral infections. Int. J. Mol. Sci. 20, 266.

Tufail, S., Badrealam, K.F., Sherwani, A., Gupta, U.D., and Owais, M. (2013). Tissue specific heterogeneity in effector immune cell response. Front. Immunol. *4*, 254.

van Beelen, A.J., Zelinkova, Z., Taanman-Kueter, E.W., Muller, F.J., Hommes, D.W., Zaat, S.A., Kapsenberg, M.L., and de Jong, E.C. (2007). Stimulation of the intracellular bacterial sensor NOD2 programs dendritic cells to promote interleukin-17 production in human memory T cells. Immunity 27, 660–669.

Wang, B., Dileepan, T., Briscoe, S., Hyland, K.A., Kang, J., Khoruts, A., and Cleary, P.P. (2010). Induction of TGF-beta1 and TGF-beta1dependent predominant Th17 differentiation by group A streptococcal infection. Proc. Natl. Acad. Sci. U S A 107, 5937–5942.

Zha, Z., Bucher, F., Nejatfard, A., Zheng, T., Zhang, H., Yea, K., and Lerner, R.A. (2017). Interferon-gamma is a master checkpoint regulator of cytokine-induced differentiation. Proc. Natl. Acad. Sci. U S A 114, E6867–E6874. iScience, Volume 23

### **Supplemental Information**

Flu Virus Attenuates Memory Clearance of *Pneumococcus* via IFN-γ-Dependent Th17 and Independent Antibody Mechanisms Ning Li, Xin Fan, Meiyi Xu, Ya Zhou, and Beinan Wang

### Supplemental Information

2	
3	Influenza A Virus Attenuates Memory Clearance of
4	Streptococcus pneumoniae via Restriction of IFN-γ
5	Dependent Th17 and Independent Antibody Responses
6	
7	Ning Li, Xin Fan, Meiyi Xu, Ya Zhou, and Beinan Wang
8	

### 9 Transparent Methods

### **Ethics statement**

11	This study was carried out in strict accordance with the recommendations in the
12	Guide for the Care and Use of Laboratory Animals of the Institute of Microbiology,
13	Chinese Academy of Sciences (IMCAS, Beijing, China). The study protocol was
14	approved by the Committee on the Ethics of Animal Experiments of IMCAS
15	(APIMCAS2016025). Mice were bred under SPF conditions in the Laboratory
16	Animal Facility at IMCAS. Animal experiments were conducted under isoflurane
17	anesthesia, and all efforts were made to minimize their suffering.
18	
19	Viral and bacterial strains
20	A/Puerto Rico/08/1934 (PR8) virus (the mouse-adapted H1N1 influenza-A virus)
21	was cultured in the allantoic cavities of 9-day-old SPF embryonated hen eggs and
22	incubated for 2 days at 35 °C. The allantoic fluid was collected and stored at $-80$ °C.
23	Viruses were quantified in Madin–Darby canine kidney cells and expressed as 50%
24	tissue culture infective dose (TCID <sub>50</sub> ). Sp strain ST556 (serotype-19F) is a clinical
25	isolate that can cause bacteremia (Li et al., 2015). GAS <sup>OVA</sup> (a group-A streptococcus
26	strain (90-226) genetically engineered to express the ovalbumin peptide (amino acids
27	323–339) on bacteria surfaces) was a kind gift from Dr. P. P. Cleary (University of
28	Minnesota, Minneapolis, MN, USA) (Park et al., 2004). These bacteria were
29	maintained on sheep-blood agar and grown in THY-Neo (Todd-Hewitt broth
30	supplemented with 2% neopeptone; BD Bioscience, San Jose, CA, USA) medium at

31	37 °C in an atmosphere of 5% CO <sub>2</sub> . Overnight cultures were harvested at the optical
32	density (O.D 560 nm) reaching to $\sim 1.1$ and used for mouse infection.
33	Colony-forming units (CFUs) were verified by plating on blood agar.
34	
35	Mice and infection
36	Female C57BL/6J and CD45.1 mice (B6.SJL- <i>Ptprc<sup>a</sup> Pepc<sup>b</sup></i> /BoyJ) (6–8 weeks)
37	were purchased from Vital River Laboratories Animal Center (Beijing, China). $Ifng^{-/-}$
38	mice (B6.129S7-Ifng <sup>tm1Ts</sup> /J) were obtained from the Jackson Laboratory (Bar
39	Harbor, ME, USA). OT- II transgenic mice (B6.Cg-Tg (TcraTcrb) 425Cbn/J) were a
40	kind gift from Dr. B. Hou (Institute of Biophysics, Chinese Academy of Sciences,
41	Beijing, China) and backcrossed for $\geq 6$ generations to B6 mice in the animal facility
42	of the Institute of Microbiology of Chinese Academy of Sciences followed by
43	intercrossing to produce homozygous offspring. Genotypes of offspring mice were
44	determined by PCRs of tail DNA provided by the Jackson Laboratory. Those mice
45	were of a C57BL/6 background, and control C57BL/6 mice were age- and
46	sex-matched when used. Mice were anesthetized (sodium pentobarbital) and
47	inoculated intratracheally (i.t.) with Sp strain ST556 ( $3.0 \times 10^7$ /mouse) in 30 µL of PBS.
48	Four weeks later, the mice were anesthetized, infected (i.t.) with PR8 at 30 TCID <sub>50</sub> in
49	30 $\mu$ L of PBS, and challenged with the same dose of <i>Sp</i> 7 days after PR8 infection.
50	Five days after challenge, lung tissue was collected for CFU counting and flow
51	cytometry (Fan et al., 2014). Single-cell suspensions of HLNs and/or lungs were
52	prepared for flow cytometry analyses. Blood taken by cardiac puncture and

53	lung-homogenate supernatants were collected and stored at $-20$ °C until ELISAs were
54	undertaken. For survival assays, Sp-preinfected mice were infected with PR8 as
55	before and challenged with a lethal dose of Sp ST556 ( $1 \times 10^8$ /mouse) 7 days after PR8
56	infection. Weight loss and survival of infected mice were documented once a day over
57	a 15-day period. In addition to mice that were found dead, mice with 30% loss of their
58	starting bodyweight were euthanized and recorded as dead. The outcome of mortality
59	was anticipated and approved by the Animal Ethics Committee of our institution. At
60	the end of the experiment, surviving mice were euthanized by exposure to increasing
61	concentrations of CO <sub>2</sub> .
62	
63	Splenocyte co-culture with HK-Sp
05	spienocyte co-culture with mk-sp
64	Four weeks after Sp infection, spleens from $Ifng^{-/-}$ mice or WT mice were
64	Four weeks after Sp infection, spleens from $Ifng^{-/-}$ mice or WT mice were
64 65	Four weeks after <i>Sp</i> infection, spleens from $Ifng^{-/-}$ mice or WT mice were removed and single-cell suspensions prepared in RPM1 1640 (Gibco, Grand Island,
64 65 66	Four weeks after <i>Sp</i> infection, spleens from $Ifng^{-/-}$ mice or WT mice were removed and single-cell suspensions prepared in RPM1 1640 (Gibco, Grand Island, NY, USA) supplemented with antibiotics and 10% fetal bovine serum (Gibco). After
64 65 66 67	Four weeks after <i>Sp</i> infection, spleens from $Ifng^{-/-}$ mice or WT mice were removed and single-cell suspensions prepared in RPM1 1640 (Gibco, Grand Island, NY, USA) supplemented with antibiotics and 10% fetal bovine serum (Gibco). After removing red blood cells with ACK lysis buffer (2.06% Tris, pH 7.65, and 0.83%
64 65 66 67 68	Four weeks after <i>Sp</i> infection, spleens from $Ifng^{-/-}$ mice or WT mice were removed and single-cell suspensions prepared in RPM1 1640 (Gibco, Grand Island, NY, USA) supplemented with antibiotics and 10% fetal bovine serum (Gibco). After removing red blood cells with ACK lysis buffer (2.06% Tris, pH 7.65, and 0.83% NH <sub>4</sub> Cl) the cell suspension was passed through a 40-mm strainer (BD Falcon,
64 65 66 67 68 69	Four weeks after <i>Sp</i> infection, spleens from $Ifng^{-/-}$ mice or WT mice were removed and single-cell suspensions prepared in RPM1 1640 (Gibco, Grand Island, NY, USA) supplemented with antibiotics and 10% fetal bovine serum (Gibco). After removing red blood cells with ACK lysis buffer (2.06% Tris, pH 7.65, and 0.83% NH <sub>4</sub> Cl) the cell suspension was passed through a 40-mm strainer (BD Falcon, Bedford, MA, USA) and plated on a 48-well, flat-bottomed plate (1×10 <sup>6</sup> , 500
64 65 67 68 69 70	Four weeks after <i>Sp</i> infection, spleens from <i>Ifng</i> <sup>-/-</sup> mice or WT mice were removed and single-cell suspensions prepared in RPM1 1640 (Gibco, Grand Island, NY, USA) supplemented with antibiotics and 10% fetal bovine serum (Gibco). After removing red blood cells with ACK lysis buffer (2.06% Tris, pH 7.65, and 0.83% NH <sub>4</sub> Cl) the cell suspension was passed through a 40-mm strainer (BD Falcon, Bedford, MA, USA) and plated on a 48-well, flat-bottomed plate ( $1 \times 10^6$ , 500 µL/well). Cells were stimulated with HK- <i>Sp</i> (multiplicity of infection = 10) with
64 65 67 68 69 70 71	Four weeks after <i>Sp</i> infection, spleens from $Ifng^{-/-}$ mice or WT mice were removed and single-cell suspensions prepared in RPM1 1640 (Gibco, Grand Island, NY, USA) supplemented with antibiotics and 10% fetal bovine serum (Gibco). After removing red blood cells with ACK lysis buffer (2.06% Tris, pH 7.65, and 0.83% NH <sub>4</sub> Cl) the cell suspension was passed through a 40-mm strainer (BD Falcon, Bedford, MA, USA) and plated on a 48-well, flat-bottomed plate (1×10 <sup>6</sup> , 500 µL/well). Cells were stimulated with HK- <i>Sp</i> (multiplicity of infection = 10) with recombinant mouse IFN- $\gamma$ (rmIFN- $\gamma$ ; GenScript, Piscataway, NJ, USA) at different

**IFN-**γ treatment

76	Mice were preinfected with Sp $(3.0 \times 10^7 / \text{mouse})$ and injected (i.v.) with 50 ng of		
77	rmIFN- $\gamma$ (GenScript) in 100 $\mu$ L of PBS and injected (i.t.) with 2 $\mu$ g of rmIFN- $\gamma$		
78	(GenScript) in 25 $\mu L$ of PBS containing 1% mouse serum or only 1% mouse serum in		
79	PBS as a control every other day for five doses. Thirty-five days after Sp preinfection,		
80	mice were challenged with Sp ( $3 \times 10^7$ /mouse) and euthanized 5 days following this		
81	challenge to determine the number of Th17 cells in lungs and IL-17 production in		
82	lung-homogenate supernatants.		
83			
84	Neutralization of IL-17 in vivo		
85	Mice were preinfected with Sp ( $3 \times 10^7$ /mouse) followed by infection with the		
86	PR8 (30 TCID <sub>50</sub> /mouse) as described in the "mice and infection" section. After PR8		
87	infection, the mice were injected intraperitoneal either with 100 $\mu$ g of an IL-17		
88	antibody (17F3; BioXCell, Lebanon, New Hampshire, USA) to block IL-17 or with		
89	an isotype control (MOPC-21; BioXCell) every other day. The mice were challenged		
90	with Sp ( $3 \times 10^7$ /mouse) 7 days after the PR8 infection and euthanized 5 days		
91	following the challenge to determine the number of CFUs in the lungs.		
92			
93	1-Methyl-D-tryptophan (D-1MT) treatment		
94	D-1MT (452483; Sigma–Aldrich, Saint Louis, MO, USA) was prepared as a		
95	20-mg/ml stock solution in 0.1 M NaOH and protected from light. Mice were		

96 preinfected with Sp ( $3 \times 10^7$ /mouse) followed by infection with PR8 ( $30 \text{ TCID}_{50}$ /mouse)

97	as described in the "mice and infection" section. Three days before PR8 infection, the			
98	mice were administered either D-1MT (2 mg/ml) in drinking water containing			
99	sweetener (Nutrasweet) to enhance palatability or drinking solvent as a control			
100	(Baban et al., 2009). The mice were challenged with Sp ( $3 \times 10^7$ /mouse) 7 days after			
101	the PR8 infection and euthanized 5 days later to determine the numbers of CFUs and			
102	Th17 cells in the lungs.			
103				
104	Adoptive cell transfer			
105	Recipient mice (CD45.1) were inoculated with PR8 or PBS 6 days before cell			
106	transfer. Donor $CD4^+$ T cells were isolated from the spleen and lymph nodes of			
107	GAS <sup>OVA</sup> -infected mice or naive OT- II transgenic mice (CD45.2) with anti-CD4			
108	microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) according to			
109	manufacturer instructions. Donor cells were labeled with 1 $\mu$ M of CFSE			
110	(Sigma–Aldrich) for 5 min at 37 °C, and $2 \times 10^6$ of these cells were transferred to each			

111 recipient by tail-vein injection. Twenty-four hours after transfer, recipient mice were

challenged with GAS<sup>OVA</sup> ( $2 \times 10^7$ /mouse) and euthanized 3 days after challenge for

- flow cytometry analyses in HLNs and lungs (Caucheteux et al., 2017).
- 114

### 115 ELISA

IL-17 (IL-17A) production was determined using a Ready-SET-Go!<sup>®</sup> ELISA kit
(eBioscience, San Diego, CA, USA) according to manufacturer instructions. Levels of

118 *Sp*-specific antibody were measured by endpoint ELISA. Briefly, 96-well plates

119	(Corning Costar, Corning, NY, USA) were coated with HK-Sp. Samples (100 $\mu$ L)
120	were added and incubated for 2 h at 37 $^{\circ}$ C. Horseradish peroxidase-conjugated goat
121	anti-mouse IgG antibody (Southern Biotech, Birmingham, AL, USA) was used as the
122	secondary antibody (1:4000 dilution). The reaction was developed by addition of
123	3,3',5,5'-Tetramethylbenzidine (TMB) (Tiangen Biotech, Beijing, China) and
124	measured by an ELx800 plate reader (BioTek, VT, USA) at 450 nm with an
125	absorbance at 570 nm as an internal control. A standard curve was generated by
126	adding twofold-diluted mouse IgG (Biovision, Martin View, CA, USA). The IgG
127	concentration was calculated based on the standard curve.
128	
129	Cellular staining and flow cytometry
130	Single-cell suspensions of HLNs and lungs were prepared in flow cytometry
130 131	Single-cell suspensions of HLNs and lungs were prepared in flow cytometry buffer (PBS with 0.01% $NaN_3$ and 0.2% bovine serum albumin). Cell staining and
131	buffer (PBS with 0.01% NaN <sub>3</sub> and 0.2% bovine serum albumin). Cell staining and
131 132	buffer (PBS with 0.01% NaN <sub>3</sub> and 0.2% bovine serum albumin). Cell staining and flow cytometry for T cells were conducted as follows. For staining of intracellular
131 132 133	buffer (PBS with 0.01% NaN <sub>3</sub> and 0.2% bovine serum albumin). Cell staining and flow cytometry for T cells were conducted as follows. For staining of intracellular cytokines, cells were stimulated with phorbol 12-myristate 13-acetate (PMA) and
131 132 133 134	buffer (PBS with 0.01% NaN <sub>3</sub> and 0.2% bovine serum albumin). Cell staining and flow cytometry for T cells were conducted as follows. For staining of intracellular cytokines, cells were stimulated with phorbol 12-myristate 13-acetate (PMA) and ionomycin, and treated with brefeldin A. Cells were stained for surface markers with
131 132 133 134 135	buffer (PBS with 0.01% NaN <sub>3</sub> and 0.2% bovine serum albumin). Cell staining and flow cytometry for T cells were conducted as follows. For staining of intracellular cytokines, cells were stimulated with phorbol 12-myristate 13-acetate (PMA) and ionomycin, and treated with brefeldin A. Cells were stained for surface markers with anti-CD3 (145-2C11; BioLegend, San Diego, CA), anti-CD4 (GK1.5; eBiosciences),
131 132 133 134 135 136	buffer (PBS with 0.01% NaN <sub>3</sub> and 0.2% bovine serum albumin). Cell staining and flow cytometry for T cells were conducted as follows. For staining of intracellular cytokines, cells were stimulated with phorbol 12-myristate 13-acetate (PMA) and ionomycin, and treated with brefeldin A. Cells were stained for surface markers with anti-CD3 (145-2C11; BioLegend, San Diego, CA), anti-CD4 (GK1.5; eBiosciences), anti-CD11c (N418; eBiosciences), anti-MHC II (M5/114.15.2; eBiosciences),
131 132 133 134 135 136 137	buffer (PBS with 0.01% NaN <sub>3</sub> and 0.2% bovine serum albumin). Cell staining and flow cytometry for T cells were conducted as follows. For staining of intracellular cytokines, cells were stimulated with phorbol 12-myristate 13-acetate (PMA) and ionomycin, and treated with brefeldin A. Cells were stained for surface markers with anti-CD3 (145-2C11; BioLegend, San Diego, CA), anti-CD4 (GK1.5; eBiosciences), anti-CD11c (N418; eBiosciences), anti-MHC II (M5/114.15.2; eBiosciences), anti-CD80 (16-10A1; BioLegend), anti-CD86 (GL1; eBiosciences), anti-CD8α

141	anti-RORyt (B2D; eBioscience) for Th17 cells and IFN-y (XMG1.2; BioLegend) for
142	Th1 cells (Wang et al., 2017). Samples were tested on a FACSAria II flow cytometer
143	(BD Biosciences) and analyzed by FlowJo (Tree Star, Ashland, OR, USA).
144	
145	Immunohistochemistry
146	Lung lobes were fixed in 4% paraformaldehyde and embedded in paraffin.
147	Immunohistochemistry was carried out as follows. Sections were blocked with 10%
148	fetal bovine serum in PBS followed by staining with anti- CCL17 antibody
149	(Sigma-Aldrich), incubated with biotinylated anti-rabbit antibody (Santa Cruz
150	Biotechnology, Santa Cruz, CA, USA) followed by an avidin-enzyme complex.
151	CCL17 expression was visualized with 3,3'-Diaminobenzidine (Sigma-Aldrich) and
152	nuclei were counterstained with hematoxylin. PBS was used for washing after each
153	step. Slides were mounted in permanent mounting media (Dako, Glostrup, Denmark)
154	and digitally scanned using Pannoramic SCAN slice-scanner (3D-Histech, Budapest,
155	Hungary) (Mikhak et al., 2013). The positive rate of CCL17 expression cells was
156	assessed quantitatively with Imagepro Plus image analysis software (Zhang et al.,
157	2013).
158	
159	RNA extraction and quantitative real-time polymerase chain reaction (qPCR)

160 Total RNA was extracted from lung tissue with TRIzol<sup>®</sup> Reagent (Invitrogen,

161 Carlsbad, CA, USA). Reverse transcription was carried out using High Capacity cDNA

162 Reverse Transcription Kit (Thermo Fisher Scientific, Waltham, MA, USA) according to

- 163 manufacturer instructions. Transcripts were amplified with SYBR Premix Ex Taq<sup>™</sup>
- 164 II (TaKaRa Biotechnology, Shiga, Japan) on a 480 II system (Roche, Basel,
- 165 Switzerland) using specific primer sets. Relative expression was evaluated using the
- 166  $2^{-\Delta\Delta Ct}$  method and expression of glyceraldehyde 3-phosphate dehydrogenase
- 167 (GAPDH) was used as the internal control. qPCR primers (forward and reverse,
- respectively) were ordered from Invitrogen and used for mouse genes: CCL17, 5'-
- 169 CAGGGATGCCATCGTGTTTC-3' and 5'- CACCAATCTGATGGCCTTCTT-3';
- 170 GAPDH, 5'-CATGGCCTTCCGTGTTCCTA-3' and
- 171 5'-GCGGCACGTCAGATCCA-3'.
- 172

### 173 Statistical analyses


- 174 Statistical analyses were undertaken using one-way ANOVA, followed by
- 175 Tukey's multiple comparisons test for comparison of three or more groups of sample
- data. The log-rank test was employed to measure survival. The 2-tailed unpaired
- 177 Mann-Whitney U nonparametric *t*-test was used for CFUs. 2-tailed unpaired *t*-test was
- employed for other variables using Prism v8.0 (GraphPad, San Diego, CA, USA).  $P \le$
- 179 0.05 was considered significant.
- 180

#### **Table S1. Key Resources Table.** Related to Figures 1-7.


REAGENT OR RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Goat anti-Mouse IgG-Fc Fragment Antibody	Bethyl	Cat#A90-131A
Goat Anti-Mouse IgG, Human ads-HRP	Southern Biotech	Cat#1030-05
Mouse IgG	BioVision	Cat#1265-100
Anti-Mouse CD3 (17A2) FITC	eBiosciences	Cat#11-0032-82


Anti-Mouse CD3 (145-2C11) PerCP	BioLegend	Cat#100325
Anti-Mouse CD4 (GK1.5) FITC	eBiosciences	Cat#11-0041-85
Anti-Mouse CD4 (GK1.5) PerCP	BioLegend	Cat#100432
Anti-Mouse CD4 (GK1.5) PE-Cyanine7	eBiosciences	Cat#25-0041-81
Anti-Mouse CD8α (53-6.7) FITC	eBiosciences	Cat#11-0081-82
Anti-Mouse NK-1.1 (PK136) PE	BioLegend	Cat#108707
Anti-Mouse CD11c (N418) PerCP-Cyanine5.5	eBiosciences	Cat#45-0114-80
Anti-Mouse MHC II (M5/114.15.2) FITC	eBiosciences	Cat#11-5321-81
Anti-Mouse CD80 (16-10A1) PE	BioLegend	Cat#104707
Anti-Mouse CD86 (GL1) APC	eBiosciences	Cat#17-0862-81
Anti-Mouse CD45.2 (104) PE	BioLegend	Cat#109808
Anti-Mouse CCR4 (2G12)	BioLegend	Cat#131211
Anti-Mouse IL-17A (eBio17B7) FITC	eBioscience	Cat#11-7177-81
Anti-Mouse IL-17A (eBio17B7) APC	eBioscience	Cat#17-7177-81
Anti-Mouse RORyt (B2D) APC	eBioscience	Cat#14-6981-80
Anti-Mouse IFN-γ (XMG1.2) PE	BioLegend	Cat#505807
Anti-Mouse IFN-γ (XMG1.2) APC	eBioscience	Cat#17-7311-81
Experimental Models: Organisms/Strains		
Mouse: C57BL/6J	Jackson	Stock#000664
	Laboratory	
Mouse: B6.SJL-Ptprc <sup>a</sup> Pepc <sup>b</sup> /BoyJ	Jackson	Stock#002014
	Laboratory	
Mouse: B6.129S7-Ifng <sup>tm1Ts</sup> /J	Jackson	Stock#002287
	Laboratory	
Mouse: B6.Cg-Tg (TcraTcrb) 425Cbn/J	Jackson	Stock# 004194
	Laboratory	
Experimental Models: Viral and Bacterial strains		
<u>^</u>	saved in our	(Li et al., 2015)
<b>Experimental Models: Viral and Bacterial strains</b> A/Puerto Rico/08/1934 (PR8) virus	saved in our laboratory	(Li et al., 2015)
A/Puerto Rico/08/1934 (PR8) virus		(Li et al., 2015) (Li et al., 2015)
A/Puerto Rico/08/1934 (PR8) virus Sp strain ST556	laboratory	
A/Puerto Rico/08/1934 (PR8) virus Sp strain ST556	laboratory clinical isolate	(Li et al., 2015)
A/Puerto Rico/08/1934 (PR8) virus Sp strain ST556	laboratory clinical isolate Dr. P. P. Cleary	(Li et al., 2015)
A/Puerto Rico/08/1934 (PR8) virus Sp strain ST556	laboratory clinical isolate Dr. P. P. Cleary University of	(Li et al., 2015)
A/Puerto Rico/08/1934 (PR8) virus Sp strain ST556	laboratory clinical isolate Dr. P. P. Cleary University of Minnesota,	(Li et al., 2015)
<u>^</u>	laboratory clinical isolate Dr. P. P. Cleary University of Minnesota, Minneapolis,	(Li et al., 2015)
A/Puerto Rico/08/1934 (PR8) virus Sp strain ST556 GAS <sup>OVA</sup>	laboratory clinical isolate Dr. P. P. Cleary University of Minnesota, Minneapolis,	(Li et al., 2015)
A/Puerto Rico/08/1934 (PR8) virus <i>Sp</i> strain ST556 GAS <sup>OVA</sup> Recombinant proteins	laboratory clinical isolate Dr. P. P. Cleary University of Minnesota, Minneapolis, MN, USA	(Li et al., 2015) (Park et al., 2004)
A/Puerto Rico/08/1934 (PR8) virus <i>Sp</i> strain ST556 GAS <sup>OVA</sup> Recombinant proteins recombinant mouse IFN-γ Chemicals	laboratory clinical isolate Dr. P. P. Cleary University of Minnesota, Minneapolis, MN, USA	(Li et al., 2015) (Park et al., 2004)
A/Puerto Rico/08/1934 (PR8) virus Sp strain ST556 GAS <sup>OVA</sup> Recombinant proteins recombinant mouse IFN-γ Chemicals Todd–Hewitt broth	laboratory clinical isolate Dr. P. P. Cleary University of Minnesota, Minneapolis, MN, USA GenScript	(Li et al., 2015) (Park et al., 2004) Cat#Z02916-500
A/Puerto Rico/08/1934 (PR8) virus <i>Sp</i> strain ST556 GAS <sup>OVA</sup> Recombinant proteins recombinant mouse IFN-γ	laboratory clinical isolate Dr. P. P. Cleary University of Minnesota, Minneapolis, MN, USA GenScript BD	(Li et al., 2015) (Park et al., 2004) Cat#Z02916-500 Cat#249240
A/Puerto Rico/08/1934 (PR8) virus Sp strain ST556 GAS <sup>OVA</sup> Recombinant proteins recombinant mouse IFN-γ Chemicals Todd–Hewitt broth Neopeptone CFSE	laboratory clinical isolate Dr. P. P. Cleary University of Minnesota, Minneapolis, MN, USA GenScript BD BD	(Li et al., 2015) (Park et al., 2004) Cat#Z02916-500 Cat#249240 Cat#211681
A/Puerto Rico/08/1934 (PR8) virus Sp strain ST556 $GAS^{OVA}$ Recombinant proteins recombinant mouse IFN- $\gamma$ Chemicals Todd–Hewitt broth Neopeptone	laboratory clinical isolate Dr. P. P. Cleary University of Minnesota, Minneapolis, MN, USA GenScript BD BD BD Sigma–Aldrich	(Li et al., 2015) (Park et al., 2004) Cat#Z02916-500 Cat#249240 Cat#211681 Cat#21888-25mg-F


Brefeldin A	eBioscience	Cat#00-4506-51
1-methyl-D-tryptophan (D-1MT)	Sigma–Aldrich	Cat# 452483-1G
Critical Commercial Assays		
CD4(L3T4) Microbeads, mouse	Miltenyi Biotec	Cat#130-117-043
Foxp3 / Transcription Factor Staining Buffer Set Kit	eBioscience	Cat#00-5523-00
Mouse IL-17A (homodimer) ELISA kit	eBioscience	Cat#88-7371-88
TRIZOL	Invitrogen	Cat#15596-026
High Capacity cDNA Reverse Transcription Kit	ThermoFisher	Cat#4368814
	Scientific	
SYBR Premix Ex Taq <sup>TM</sup> II	TaKaRa	Cat#RR820A
Oligonucleotides		
CCL17 Forward CAGGGATGCCATCGTGTTTC	Invitrogen DNA	N/A
	Technologies	
CCL17 Reverse CACCAATCTGATGGCCTTCTT	Invitrogen DNA	N/A
	Technologies	
GAPDH Forward CATGGCCTTCCGTGTTCCTA	Invitrogen DNA	N/A
	Technologies	
GAPDH Reverse GCGGCACGTCAGATCCA	Invitrogen DNA	N/A
	Technologies	
Software		
PRISM Version 8	Graphpad	https://www.graphp
		ad.com/scientific-so
		ftware/prism/
FlowJo Version 7	Tree Star	https://www.flowjo.
		com/solutions/flowj
		o/downloads
Adobe Creative Cloud	Adobe	https://www.adobe.c
		om/creativecloud.ht
		ml#


























235 *t*-test.




236

Figure S5. The proliferation of Th17 cells in response to secondary Sp infection

**was suppressed in IAV-infected mice.** Related to Figure 5. The adoptive transfer was

done as described in Figure 5A. Dot plots represent the expression of (A) CD4 and

- 240 CD45.2 on gated lymphocytes and (B) CD4 and ROR $\gamma$ t on gated CD4<sup>+</sup> CD45.2<sup>+</sup> T
- cells in the hilar lymph nodes (HLNs).



243 244

mice in response to secondary *Sp* infection. Related to Figure 6. Mice were infected, challenged, and euthanized as described in Figure 1B. (A) The proportion of CCR4<sup>+</sup>

cells among the pulmonary  $CD4^+T$  cell population and (B) the number of pulmonary

- 248 CCR4<sup>+</sup> CD4<sup>+</sup> T cells were determined by flow cytometry (n = 6-10). Data are
- represented as mean +/- SEM of 2–3 independent experiments. \*p < 0.05, \*\*p < 0.01.
- 250 (A and B) One-way ANOVA, followed by Tukey's multiple comparisons test. The
- adoptive transfer was done as described in Figure 5A. Dot plots represent the
- expression of (C) CD4 and CD45.2 on gated lymphocytes and (D) CD4 and RORγt
- 253 on gated  $CD4^+ CD45.2^+ T$  cells in the lungs.

254

### 255 **REFERENCES**

Baban, B., Chandler, P.R., Sharma, M.D., Pihkala, J., Koni, P.A., Munn, D.H., and Mellor, A.L. (2009). IDO
activates regulatory T cells and blocks their conversion into Th17-like T cells. Journal of immunology
(Baltimore, Md : 1950) *183*, 2475-2483.

- 259 Caucheteux, S.M., Hu-Li, J., Mohammed, R.N., Ager, A., and Paul, W.E. (2017). Cytokine regulation of
- 260 lung Th17 response to airway immunization using LPS adjuvant. Mucosal Immunol *10*, 361-372.
- Fan, X., Wang, X., Li, N., Cui, H., Hou, B., Gao, B., Cleary, P.P., and Wang, B. (2014). Sortase A induces
- 262 Th17-mediated and antibody-independent immunity to heterologous serotypes of group A

263 streptococci. PloS one *9*, e107638.

- Li, N., Ren, A., Wang, X., Fan, X., Zhao, Y., Gao, G.F., Cleary, P., and Wang, B. (2015). Influenza viral
- 265 neuraminidase primes bacterial coinfection through TGF-beta-mediated expression of host cell
- 266 receptors. Proc Natl Acad Sci U S A *112*, 238-243.
- 267 Mikhak, Z., Strassner, J.P., and Luster, A.D. (2013). Lung dendritic cells imprint T cell lung homing and
- promote lung immunity through the chemokine receptor CCR4. J Exp Med *210*, 1855-1869.
- 269 Park, H.S., Costalonga, M., Reinhardt, R.L., Dombek, P.E., Jenkins, M.K., and Cleary, P.P. (2004). Primary
- 270 induction of CD4 T cell responses in nasal associated lymphoid tissue during group A streptococcal
- 271 infection. Eur J Immunol *34*, 2843-2853.
- 272 Wang, X., Fan, X., Bi, S., Li, N., and Wang, B. (2017). Toll-like Receptors 2 and 4-Mediated Reciprocal
- Th17 and Antibody Responses to Group A Streptococcus Infection. The Journal of infectious diseases*215*, 644-652.
- 275 Zhang, X., Wang, H., and Wang, J. (2013). Expression of HMGB1 and NF-kappaB p65 and its
- significance in non-small cell lung cancer. Contemp Oncol (Pozn) 17, 350-355.